France’s Innate Pharma has gained rights to AstraZeneca's recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.
AstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in patients who have just been treated with chemo, in trial re
Clovis’ PARP inhibitor drug Rubraca is showing promise in prostate cancer, according to data released at this year's ESMO conference, as the company hopes to steal a march on AstraZeneca an
